drugset / Trial / NCT00504907
Safety Study of Oral BTA9881 to Treat RSV Infection
RandomizedSingle-groupQuadruple-blindTreatment
Summary
This is a placebo-controlled, double-blind, randomised, single dose escalation Phase I clinical trial to determine the safety and tolerability of BTA9881 administered orally to healthy subjects
Timeline
- Start
- 2007-07
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BTA9881 | Small molecule | 10 mg | Oral |
| Subject | BTA9881 | Small molecule | 25 mg | Oral |
| Subject | BTA9881 | Small molecule | 50 mg | Oral |
| Subject | BTA9881 | Small molecule | 100 mg | Oral |
| Subject | BTA9881 | Small molecule | 200 mg | Oral |
| Subject | BTA9881 | Small molecule | 400 mg | Oral |